437 related articles for article (PubMed ID: 30209552)
1. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.
Zavalishina L; Tsimafeyeu I; Povilaitite P; Raskin G; Andreeva Y; Petrov A; Kharitonova E; Rumyantsev A; Pugach I; Frank G; Tjulandin S
Virchows Arch; 2018 Dec; 473(6):719-724. PubMed ID: 30209552
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.
Hodgson A; Slodkowska E; Jungbluth A; Liu SK; Vesprini D; Enepekides D; Higgins K; Katabi N; Xu B; Downes MR
Am J Surg Pathol; 2018 Aug; 42(8):1059-1066. PubMed ID: 29750666
[TBL] [Abstract][Full Text] [Related]
3. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
[TBL] [Abstract][Full Text] [Related]
4. Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma.
Zajac M; Scott M; Ratcliffe M; Scorer P; Barker C; Al-Masri H; Rebelatto MC; Walker J
Diagn Pathol; 2019 Sep; 14(1):99. PubMed ID: 31477145
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies.
Reis H; Serrette R; Posada J; Lu V; Chen YB; Gopalan A; Fine SW; Tickoo SK; Sirintrapun SJ; Iyer G; Funt SA; Teo MY; Rosenberg JE; Bajorin DF; Dalbagni G; Bochner BH; Solit DB; Reuter VE; Al-Ahmadie HA
Am J Surg Pathol; 2019 Jul; 43(7):920-927. PubMed ID: 31135485
[TBL] [Abstract][Full Text] [Related]
6. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
Eckstein M; Erben P; Kriegmair MC; Worst TS; Weiß CA; Wirtz RM; Wach S; Stoehr R; Sikic D; Geppert CI; Weyerer V; Bertz S; Breyer J; Otto W; Keck B; Burger M; Taubert H; Weichert W; Wullich B; Bolenz C; Hartmann A; Erlmeier F
Eur J Cancer; 2019 Jan; 106():234-243. PubMed ID: 30528808
[TBL] [Abstract][Full Text] [Related]
7. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
Scorer P; Scott M; Lawson N; Ratcliffe MJ; Barker C; Rebelatto MC; Walker J
Diagn Pathol; 2018 Jul; 13(1):47. PubMed ID: 30041679
[TBL] [Abstract][Full Text] [Related]
8. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.
Munari E; Rossi G; Zamboni G; Lunardi G; Marconi M; Sommaggio M; Netto GJ; Hoque MO; Brunelli M; Martignoni G; Haffner MC; Moretta F; Pegoraro MC; Cavazza A; Samogin G; Furlan V; Mariotti FR; Vacca P; Moretta L; Bogina G
Am J Surg Pathol; 2018 Oct; 42(10):1384-1389. PubMed ID: 29901568
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
Rugo HS; Loi S; Adams S; Schmid P; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Winer EP; Kockx MM; Peeters D; Chui SY; Lin JC; Nguyen-Duc A; Viale G; Molinero L; Emens LA
J Natl Cancer Inst; 2021 Nov; 113(12):1733-1743. PubMed ID: 34097070
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study.
Paliogiannis P; Lobrano R; Bella MA; Fara A; Uras MG; Pinna MA; Tedde A; Madonia M; Zinellu A; Cossu A
Ann Diagn Pathol; 2024 Apr; 69():152267. PubMed ID: 38266544
[TBL] [Abstract][Full Text] [Related]
12. SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3.
Pang JB; Castles B; Byrne DJ; Button P; Hendry S; Lakhani SR; Sivasubramaniam V; Cooper WA; Armes J; Millar EKA; Raymond W; Roberts-Thomson S; Kumar B; Burr M; Selinger C; Harvey K; Chan C; Beith J; Clouston D; O'Toole SA; Fox SB;
Am J Surg Pathol; 2021 Aug; 45(8):1108-1117. PubMed ID: 34232604
[TBL] [Abstract][Full Text] [Related]
13. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B
Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
[TBL] [Abstract][Full Text] [Related]
15. A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer.
Noske A; Ammann JU; Wagner DC; Denkert C; Lebeau A; Sinn P; Kreipe HH; Sommer U; Baretton G; Steiger K; Kiechle M; Hieke-Schulz S; Flores M; Roth W; Weichert W
Histopathology; 2021 Mar; 78(4):567-577. PubMed ID: 32936950
[TBL] [Abstract][Full Text] [Related]
16. Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma.
Huang X; Ding Q; Guo H; Gong Y; Zhao J; Zhao M; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
Hum Pathol; 2021 Feb; 108():42-50. PubMed ID: 33221342
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.
Ivanova M; Frascarelli C; Cerbelli B; Pignataro MG; Pernazza A; Venetis K; Sajjadi E; Criscitiello C; Curigliano G; Guerini-Rocco E; Graziano P; Martini M; d'Amati G; Fusco N
Hum Pathol; 2024 Feb; 144():22-27. PubMed ID: 38278450
[TBL] [Abstract][Full Text] [Related]
18. Programmed death ligand-1 (PD-L1) immunohistochemical assessment using the QR1 clone in muscle-invasive urothelial carcinomas: a comparison with reference clones 22C3 and SP263.
Loghin A; Nechifor-Boilă A; Borda A; Nechifor-Boilă IA; Voidazan S; Decaussin-Petrucci M
Virchows Arch; 2022 Feb; 480(2):303-313. PubMed ID: 34669047
[TBL] [Abstract][Full Text] [Related]
19. Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection.
Munari E; Querzoli G; Brunelli M; Marconi M; Sommaggio M; Cocchi MA; Martignoni G; Netto GJ; Caliò A; Quatrini L; Mariotti FR; Luchini C; Girolami I; Eccher A; Segala D; Ciompi F; Zamboni G; Moretta L; Bogina G
Front Immunol; 2022; 13():954910. PubMed ID: 35967344
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer.
Song P; Guo L; Li W; Zhang F; Ying J; Gao S
J Immunother; 2019 Jan; 42(1):23-28. PubMed ID: 30407231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]